NCT06438445 Effects of Royal Jelly Supplementation in Chronic Kidney Disease
| NCT ID | NCT06438445 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universidade Federal Fluminense |
| Condition | Kidney Failure, Chronic |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2024-07-30 |
| Primary Completion | 2026-12-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 30 participants in total. It began in 2024-07-30 with a primary completion date of 2026-12-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this study is to evaluate the effects of royal jelly on inflammation and cellular senescence in patients with chronic kidney disease (CKD) on hemodialysis (HD).
Eligibility Criteria
Inclusion Criteria: * patients with CKD undergoing hemodialysis for more than 6 months * patients with arteriovenous fistula (AVF) as vascular access. Exclusion Criteria: * pregnant, * lactating, * smoker * patients using antibiotics and antioxidant supplements in the last three months * patients with autoimmune and infectious diseases, * patients with cancer, liver disease, and AIDS
Contact & Investigator
Denise Mafra
STUDY DIRECTOR
Universidade Federal Fluminense
Frequently Asked Questions
Who can join the NCT06438445 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Kidney Failure, Chronic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06438445 currently recruiting?
Yes, NCT06438445 is actively recruiting participants. Contact the research team at dmafra30@gmail.com for enrollment information.
Where is the NCT06438445 trial being conducted?
This trial is being conducted at Rio de Janeiro, Brazil.
Who is sponsoring the NCT06438445 clinical trial?
NCT06438445 is sponsored by Universidade Federal Fluminense. The principal investigator is Denise Mafra at Universidade Federal Fluminense. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.